Martins, E.Lebreiro, A.Sousa, C.Leite, S.Sousa, A.Belo, A.Brito, DulceCardim, N.2019-11-132019-11-132018European Heart Journal, Volume 39, Issue suppl_1, August 2018, ehy563.P35440195-668Xhttp://hdl.handle.net/10451/40136© The European Society of Cardiology 2018. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.orgIntroduction: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are not considered disease-modifying drugs in hypertrophic cardiomyopathy (HCM) and their use is usually dependent on other clinical indications. Few data exist about the use of ACEI/ARB in HC in the real world, particularly in patients with intraventricular obstruction. Objective: In this study, we sought to determine the frequency of ACEI / ARB therapy in patients with HCM and the predictors for their use.engAngiotensin-converting enzyme inhibitorsHypertrophic cardiomyopathyjournal article10.1093/eurheartj/ehy563.P3544